Chronic obstructive pulmonary disease

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Virology, Conference, Heart, Partnership, RSV, FDA, Medication, Chronic obstructive pulmonary disease, Disease, Hepatitis, KIT, Viral load, ADME, Pharmacokinetics, Asthma, COVID-19, CSU, Webcast, Patient, Safety, Therapy, Fast Track, Pharmaceutical industry

Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.

Key Points: 
  • Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.
  • The company has developed novel, potent and selective oral inhibitors of KIT, which are now being optimized in preclinical development.
  • Enanta will present new preclinical data on its prototype KIT inhibitor at the J.P. Morgan Conference and is targeting the selection of a development candidate in 2024.
  • A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Conference, Atopic dermatitis, COPD, Chronic obstructive pulmonary disease, SAN, Therapy, I&I, Asthma, News

SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T.

Key Points: 
  • SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T.
  • / 10:30 a.m. E.T.
  • A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, Blood, International, Chronic obstructive pulmonary disease, Cough, Bromide, Common, Headache, Nose, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, COPD, Blood, International, Chronic obstructive pulmonary disease, Bromide, Common, Headache, Nose, Cough, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, Wheeze, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Daxas, roflumilast, Date of authorisation: 05/07/2010, Revision: 20, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, Agency, INN, ATC, Insomnia, COPD, International, Chronic obstructive pulmonary disease, European, Headache, Disease, Nausea, Language, FEV1, Abdominal pain, Gestational sac, Inflammation, Appetite, PDE4, Observational study, European Medicines Agency, Tablet, Chronic pain, Select, Bronchitis, Safety, Anatomy, IIA, History, Medical device

Human medicines European public assessment report (EPAR): Daxas, roflumilast, Date of authorisation: 05/07/2010, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Daxas, roflumilast, Date of authorisation: 05/07/2010, Revision: 20, Status: Authorised

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Retrieved on: 
Tuesday, January 2, 2024
Hercules, VRNA, Health care, COPD, Chronic obstructive pulmonary disease, Pharming, Growth, Patient, Pharma, Creditor, Senior

LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”) providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) (collectively, the “Lenders”).

Key Points: 
  • LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”) providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) (collectively, the “Lenders”).
  • The debt facility replaces the existing facility of up to $150 million with an affiliate of Oxford.
  • Verona Pharma will pay only interest on the outstanding loans under the debt facility for the first 53 months with the outstanding principal of the loans under the debt facility amortized over the subsequent 7 months.
  • The $20 million drawn and fees and associated costs due to Oxford on the discharge of the existing debt facility will be paid to Oxford on closing of the debt facility.

Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally

Retrieved on: 
Thursday, December 7, 2023
Urinary tract infection, JAMA, ASX, Risk, Woman, COPD, Prevalence, Disease, Lung cancer, SAN, RMD, Education, Gestational sac, Low, Air pollution, Emphysema, Chronic obstructive pulmonary disease, American Medical Association, JAMA Network Open, Tobacco smoking, World Health Organization, ResMed, Growth, Patient, Bronchitis, Journal, Female, Dust, Pharmaceutical industry

According to the World Health Organization , COPD is the third deadliest disease in the world.

Key Points: 
  • According to the World Health Organization , COPD is the third deadliest disease in the world.
  • Today, there are an estimated 480 million people who suffer from COPD.
  • This study in JAMA Network Open projects the increased regional and global burden of COPD by 2050 through an analysis of historical COPD prevalence and data on COPD risk factors such as tobacco smoking, outdoor air pollution, and household air pollution.
  • “The disproportionate growth of COPD among women is a critical finding as COPD has not always been as prevalent in women.

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

Retrieved on: 
Thursday, December 7, 2023
IRAK4, Dupilumab, Atopic dermatitis, Potential, RSV, Multiple sclerosis, COPD, Research and development, Vaccine, Chronic obstructive pulmonary disease, Asthma, Acne, Growth, Ambition, Webcast, Patient, Development, Fine chemical

Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.

Key Points: 
  • Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.
  • Sanofi will also share its ambitions to break efficacy ceilings and expand into new indications, generating a steady flow of predominantly wholly-owned new assets.
  • Vaccines - Sanofi reiterates its expectation to generate over €10 billion of annual sales by 2030, including the recent launch of Beyfortus®.
  • With an unprecedented number of potential blockbuster assets in our pipeline, we will showcase how we become a development-driven, tech-powered biopharma company, committed to serving patients and accelerating growth.

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

Retrieved on: 
Friday, November 17, 2023
COPD, VRNA, US Foods, Patient, Chronic obstructive pulmonary disease, Pharming

LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition of his exemplary leadership.

Key Points: 
  • LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition of his exemplary leadership.
  • David Zaccardelli, Pharm.
  • D., President and CEO of Verona Pharma said: “I am honored to receive this prestigious award and would like to thank the dedicated and talented team at Verona Pharma for their efforts to bring our first-in-class treatment to the millions of chronic obstructive pulmonary disease (“COPD”) patients worldwide who remain symptomatic.
  • Ensifentrine is under review by the US Food and Drug Administration for the maintenance treatment of COPD and this achievement would not have been possible without their hard work.”
    For further information please contact:

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
European Academy of Management, Safety, SAN, General counsel, Research and development, Therapy, IND, Initial public offering, Exercise, Clinical trial, Administration, Aulus Cornelius Cossus Arvina, Patient, TARC, G&A, Pharmacokinetics, Atopic dermatitis, Conference, IPO, Half-life, R, Growth, Chronic obstructive pulmonary disease, Congress, Health, I&I, Asthma, Inflammation, Vaccine, Pharmaceutical industry, COPD, Apsis, Venereology, Dermatology

SAN FRANCISCO and WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today provided business updates and reported third quarter 2023 financial results.

Key Points: 
  • “I am proud of our team’s execution during the third quarter and 2023 overall.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $17.1 million, compared to $9.9 million for the third quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.2 million, compared to $0.6 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $20.8 million, compared to the net loss for the third quarter of 2022 which was $19.7 million.